NCT03366428 - Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 26, 2017

Primary Completion Date

December 5, 2018

Study Completion Date

February 19, 2021

Conditions

Malignant Neoplasm of Breast

Interventions

DRUG

DS-8201a

DS-8201a is supplied as a lyophilized powder which is reconstituted for infusion

Trial Locations (7)

Kanagawa Cancer Center, Yokohama

National Cancer Center Hospital, Chuo Ku

The Cancer Institute Hospital of Japanese Foundation For Cancer Research, Koto-Ku

Toranomon Hospital, Minato-Ku

National Hospital Organization Kyushu Cancer Center, Fukuoka

Social Medical Corporation Hakuaikai Sagara Hospital, Kagoshima

Shizuoka Cancer Center, Shizuoka